Free tool
FAERS Monitor: Cambia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022165 or its brand name (Cambia, Diclofenac Potassium). Reports on generic versions are filed under their own applications.
Reports
10,696
Serious
8,489
79% of reports
Hospitalization
4,891
Death reported
4,383
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,897
- rheumatoid arthritis2,674
- fatigue2,642
- off label use2,597
- pain2,541
- rash2,540
- systemic lupus erythematosus2,494
- joint swelling2,437
- wound2,383
- pemphigus2,317
- glossodynia2,295
- synovitis2,293
- infusion related reaction2,269
- hand deformity2,260
- abdominal discomfort2,259
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 59 |
| 2007 | 9 |
| 2008 | 16 |
| 2009 | 14 |
| 2010 | 15 |
| 2011 | 66 |
| 2012 | 45 |
| 2013 | 54 |
| 2014 | 71 |
| 2015 | 205 |
| 2016 | 894 |
| 2017 | 511 |
| 2018 | 486 |
| 2019 | 642 |
| 2020 | 597 |
| 2021 | 499 |
| 2022 | 689 |
| 2023 | 845 |
| 2024 | 2,081 |
| 2025 | 1,931 |
| 2026 | 954 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,463 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 2,317 | 447.0 | 429.1 | 840,382 |
| hand deformitySignal | 2,260 | 409.0 | 392.6 | 761,728 |
| synovitisSignal | 2,293 | 286.3 | 275.2 | 569,338 |
| glossodyniaSignal | 2,295 | 224.5 | 215.9 | 458,620 |
| woundSignal | 2,383 | 183.2 | 176.4 | 395,322 |
| systemic lupus erythematosusSignal | 2,494 | 148.5 | 143.3 | 340,248 |
| infusion related reactionSignal | 2,269 | 69.7 | 67.1 | 148,704 |
| rheumatoid arthritisSignal | 2,674 | 47.4 | 45.9 | 119,216 |
| joint swellingSignal | 2,437 | 40.5 | 39.1 | 92,475 |
| abdominal discomfortSignal | 2,259 | 26.8 | 25.9 | 55,836 |
| rashSignal | 2,540 | 11.5 | 11.1 | 24,761 |
| painSignal | 2,541 | 8.2 | 7.9 | 16,379 |
| fatigueSignal | 2,642 | 6.7 | 6.5 | 13,233 |
| off label useSignal | 2,597 | 5.8 | 5.7 | 10,849 |
| drug ineffectiveSignal | 2,897 | 4.3 | 4.2 | 7,894 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.